Mereo BioPharma Group plc (MREO) |
|
1.18 -0.02 (-1.67%)
|
08-18 06:14 |
|
Open: |
1.16 |
Pre. Close: |
1.2 |
|
High:
|
1.21 |
Low:
|
1.16 |
|
Volume:
|
503,687 |
Market Cap:
|
138(M) |
|
|
|
|
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.21 - 1.22 |
1.22 - 1.23 |
|
Low:
|
1.14 - 1.15 |
1.15 - 1.16 |
|
Close:
|
1.17 - 1.18 |
1.18 - 1.19 |
|
Technical analysis |
as of: 2022-08-17 4:25:12 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.81 One year: 2.13 |
| Support: |
Support1: 1.11 Support2: 0.92 |
| Resistance: |
Resistance1: 1.55 Resistance2: 1.83 |
| Pivot: |
1.21 |
| Moving Average: |
MA(5): 1.23 MA(20): 1.27
MA(100): 0.98 MA(250): 1.48 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 33.2 %D(3): 38.7  |
| RSI: |
RSI(14): 44.7 |
| 52-week: |
High: 2.93 Low: 0.3 |
| Average Vol(K): |
3-Month: 7,703 (K) 10-Days: 1,361 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MREO ] has closed above bottom band by 36.0%. Bollinger Bands are 57.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 16 Aug 2022
European ADRs Nudge Lower in Tuesday Trading - InvestorsObserver
Tue, 16 Aug 2022
Cobra Resources provides Wudinna Project update - Global Mining Review
Fri, 12 Aug 2022
Is Mereo BioPharma Group plc - ADR (MREO) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Fri, 12 Aug 2022
Mereo BioPharma Group (NASDAQ:MREO) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Wed, 03 Aug 2022
American Rare Earths" assays up to 5,065 ppm total rare earth oxide provide upside potential at Halleck Creek - Proactive Investors USA
Fri, 17 Jun 2022
Mereo BioPharma: Activist Pressure In A Net-Net Biopharma - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
109 (M) |
| Shares Float |
50 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
79.7 (%) |
|
Shares Short
|
5,210 (K) |
|
Shares Short P.Month
|
3,560 (K) |
Stock Financials |
|
EPS
|
-0.36 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.81 |
|
Profit Margin (%)
|
34.9 |
|
Operating Margin (%)
|
-57.5 |
|
Return on Assets (ttm)
|
-13.9 |
|
Return on Equity (ttm)
|
34.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.17 |
|
Sales Per Share
|
0.33 |
|
EBITDA (p.s.)
|
-0.2 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-5 (M) |
|
Levered Free Cash Flow
|
-7 (M) |
Stock Valuations |
|
PE Ratio
|
-3.32 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.43 |
|
Price to Sales
|
3.52 |
|
Price to Cash Flow
|
-24.53 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
